Durvalumab New Standard in Stage III Unresectable Lung Cancer Durvalumab New Standard in Stage III Unresectable Lung Cancer

Now with data showing an overall survival advantage, the immunotherpy sets new standard of care in stage III unresectable lung cancer following concurrent chemotherapy and radiotherapy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news